News & Updates
Filter by Specialty:
IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension
Use of intravenous (IV) antihypertensive treatment appears to increase the risk of myocardial injury in patients who develop severe hypertension during hospitalization and without acute target end organ damage, reveals a recent study.
IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension
21 Jan 2023
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
20 Jan 2023
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.
Can RA patients taper MTX from targeted therapy?
18 Jan 2023
Fluvoxamine strikes out in mild-to-moderate COVID-19
Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.